You are here » Home » Companies » Company Overview » Claris Lifesciences Ltd

Claris Lifesciences Ltd.

BSE: 533288 Sector: Health care
NSE: N.A. ISIN Code: INE562G01018
BSE LIVE 15:40 | 18 Aug 360.00 -2.75
(-0.76%)
OPEN

361.10

HIGH

364.40

LOW

358.10

NSE 05:30 | 01 Jan Stock Is Not Traded.
OPEN 361.10
PREVIOUS CLOSE 362.75
VOLUME 29030
52-Week high 430.10
52-Week low 217.30
P/E 257.14
Mkt Cap.(Rs cr) 1,965
Buy Price 361.20
Buy Qty 3.00
Sell Price 0.00
Sell Qty 0.00
OPEN 361.10
CLOSE 362.75
VOLUME 29030
52-Week high 430.10
52-Week low 217.30
P/E 257.14
Mkt Cap.(Rs cr) 1,965
Buy Price 361.20
Buy Qty 3.00
Sell Price 0.00
Sell Qty 0.00

Claris Lifesciences Ltd. (CLARISLIFESCIEN) - Chairman Speech

Company chairman speech

Dear Stakeholders

With utmost pleasure I share the key highlights of our performance with you throughthis Annual Report for the year 2015-16. I hope you feel the same satisfaction and pridethat we felt while analyzing our growth trajectory during the compilation of thisdocument.

During the year we focused mainly on the expansion of the newly formed wholly ownedsubsidiary Claris Injectables Limited. Special emphasis has been laid to widen thehorizons of our specialty injectables business in the USA market. Essential changes havebeen undertaken at the core level to strengthen the organizational structure of ClarisInjectables Limited (India) and Claris Lifesciences Inc. (USA) so as to fortify ourmanufacturing capabilities and penetrate deeper in flourishing markets. During the yearthe Company also installed two lines at the new plant and introduced two new technologiesin form of Lyophilization and Asceptic Filling. These two technologies will help theCompany develop file and sell high value products in the USA going forward.

In addition to the improvement of manufacturing processes including automation in thepackaging sections of the manufacturing facility in 2014-15 production capacities havealso been enhanced in 2015-16 to facilitate the growing demand of our products. Togetherthese advancements have provided an impetus to our efforts and have put us on the pathtowards our goal of increasing our market share for existing products and launching newproducts in the USA. The Company continues to target its 100 ANDAs pipeline in the USA by2020. On the same lines I am happy to state that 52% of our Speciality InjectablesBusiness revenue has been generated from the USA.

We are well on track to roll out 25 products over the next three years which arecapable of solidifying company’s position in the USA and Regulated Markets.

Our growth is catapulted to newer heights year-on-year coupled with our focus onquality technology innovation strength of technical know-how expertise inmanufacturing and marketing injectables products that has helped us carve a strongfoothold in the global arena through establishing a niche position for ourselves.

While the business goals have remained our priority simultaneously we have ensuredsincere involvement in corporate social responsibility. We have continued our support inthe areas of promoting sports healthcare education and culture amongst others.

We have been unapologetic in our approach and insistence for finest product andmanagement quality which has time and again been recognized by industry stalwarts. Forthe sixth consecutive year we have been recognized as one of the ‘India's BestCompanies to Work for’ by The Economic Times and Great Place to WorkR Institute. Therecognition attests our unwavering belief that ‘people are everything’.

May it be human resource technological infrastructure manufacturing and researchexpertise or marketing networks we are incessant in our pursuit for world-class quality;we are poised to surge ahead.

I wholeheartedly appreciate the ceaseless faith and encouragement of all ourstakeholders which time and again fuel Claris with an unrelenting urge to continueresearching innovating manufacturing and marketing finest quality lifesaving productsto preserve Earth’s most precious resource… Human Lives.

Our approach has always been to develop progressive cutting-edge and sustainableproducts with an unrelenting focus on quality.

Our growth is catapulted to newer heights year-on-year coupled with our focus onquality technology innovation strength of technical know-how expertise inmanufacturing and marketing injectables products.